In the past week, CNTA stock has gone up by 9.53%, with a monthly gain of 20.34% and a quarterly surge of 32.19%. The volatility ratio for the week is 6.84%, and the volatility levels for the last 30 days are 6.74% for Centessa Pharmaceuticals plc ADR The simple moving average for the last 20 days is 15.38% for CNTA’s stock, with a simple moving average of 33.19% for the last 200 days.
Is It Worth Investing in Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Right Now?
Moreover, the 36-month beta value for CNTA is 1.39. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNTA is 67.72M and currently, short sellers hold a 2.04% of that float. On August 14, 2024, CNTA’s average trading volume was 243.22K shares.
CNTA) stock’s latest price update
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) has experienced a rise in its stock price by 8.54 compared to its previous closing price of 11.01. However, the company has seen a gain of 9.53% in its stock price over the last five trading days. globenewswire.com reported 2024-08-13 that BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the second quarter ended June 30, 2024.
Analysts’ Opinion of CNTA
Many brokerage firms have already submitted their reports for CNTA stocks, with Oppenheimer repeating the rating for CNTA by listing it as a “Outperform.” The predicted price for CNTA in the upcoming period, according to Oppenheimer is $14 based on the research report published on July 18, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $11, previously predicting the price at $4. The rating they have provided for CNTA stocks is “Buy” according to the report published on November 15th, 2023.
Morgan Stanley gave a rating of “Equal-Weight” to CNTA, setting the target price at $8 in the report published on October 26th of the previous year.
CNTA Trading at 23.93% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.02% of loss for the given period.
Volatility was left at 6.74%, however, over the last 30 days, the volatility rate increased by 6.84%, as shares surge +28.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.00% upper at present.
During the last 5 trading sessions, CNTA rose by +12.19%, which changed the moving average for the period of 200-days by +80.27% in comparison to the 20-day moving average, which settled at $10.49. In addition, Centessa Pharmaceuticals plc ADR saw 50.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from Anderson Karen M., who sale 51,160 shares at the price of $11.88 back on Mar 25 ’24. After this action, Anderson Karen M. now owns 71,525 shares of Centessa Pharmaceuticals plc ADR, valued at $607,960 using the latest closing price.
Rotman Harris, the SVP Regulatory Affairs of Centessa Pharmaceuticals plc ADR, sale 4,267 shares at $8.10 during a trade that took place back on Feb 01 ’24, which means that Rotman Harris is holding 62,625 shares at $34,574 based on the most recent closing price.
Stock Fundamentals for CNTA
Current profitability levels for the company are sitting at:
- -22.54 for the present operating margin
- 0.9 for the gross margin
The net margin for Centessa Pharmaceuticals plc ADR stands at -22.81. The total capital return value is set at -0.42. Equity return is now at value -55.88, with -39.78 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.96. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -30.46.
Currently, EBITDA for the company is -171.13 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 167.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.29.
Conclusion
To wrap up, the performance of Centessa Pharmaceuticals plc ADR (CNTA) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
